KINETIC-TECHNOLOGIES
Power management and video/audio interface IC leader Kinetic Technologies announced today the KTA1140 IEEE 802.3bt-compliant Powered Device Interface IC and the KTB1095 synchronous flyback control IC with integrated digital isolated feedback as the latest additions to their PoE and DC-DC Converter product lines.
Fully compliant with IEEE 802.3bt, 802.3at and 802.3af standards, the KTA1140 integrates input surge protection, a PD controller with 100V, low resistance 0.1Ω hot-swap MOSFET, which fully supports input power levels up to 90W. The PD controller also includes eight-event classification, ATDET, PD Detect, over temperature protection and under voltage lockout (UVLO). The KTA1140 is also designed to provide seamless support for local supplies down to 9.5V.
The KTB1095 is a highly integrated synchronous flyback converter with internal feedback utilizing a 3000VRMS digital isolator, designed to eliminate the need for an external opto-coupler, reducing cost and size. Operating over a wide operating voltage range from 5V to 100V, the KTB1095 includes both primary and secondary side, high current MOSFET drivers and employs current-mode constant on-time control for fast transient response. Featuring an adjustable soft-start function to limit start-up in-rush current, the KTB1095 also includes input voltage UVLO, output over-voltage-protection (OVP), cycle-by-cycle current limit, short-circuit protection and thermal shutdown.
“Our goal at Kinetic is to make it as easy as possible for our customers to design their power supplies,” said Erik Ogren, Kinetic Technologies’ Senior Director of Marketing. “The KTA1140 supports Class 8, 90W designs with its ultra-low resistance hot-swap MOSFET and simplifies system designs with local voltage support. KTB1095 takes advantage of Kinetic’s Tru-Iso™ technology to deliver integrated 3000V-rms on-chip digital isolator feedback, reducing BOM count and PCB area.”
KTA1140 and KTB1095 are sampling now, with production expected to begin in the first quarter of 2023.
Visit Kinetic Technologies for further information.
Key Product Highlights:
KTA1140 – PoE 802.3bt PD Interface
-
Fully supports IEEE® 802.3bt
- Input Power Levels Up to 90W
- Class 0-8 for PoE PD
- Compatible with IEEE® 802.3af/at
- IEC 61000-4-2/3/4/5/6 requirements for EMC
- Seamless support for local power down to 9.5V
- Programmable DC current limit
- Low resistance (typ. 0.1Ω) Hot Swap MOSFET
- 5x5 mm, 20 lead QFN Package
KTB1095 – 100V Synchronous Flyback Controller with Digital Isolation
- Wide 5V to 100V Operating Voltage Range
-
Integrated Digital Isolator Feedback
- 3000V-rms Integrated Isolation
- ±1% Voltage Reference
-
Integrated primary and secondary side MOSFET Drivers
- 3A Sink / 2A Source driving capability
- Adjustable Switching Frequency from 100kHz to 700kHz
- Integrated Protection: Cycle-by-cycle current limit, Input UVLO, OCP, SCP, TSP
- SOIC-16 Wide Body (10.3mm x 7.5mm) Package
About Kinetic Technologies
Kinetic Technologies is a global designer, developer, and provider of proprietary and innovative high-performance analog and mixed-signal semiconductor products for a wide variety of markets. Kinetic’s products help its customers efficiently regulate power, intelligently protect their devices from harmful voltage and current spikes, and deliver high-bandwidth, low-latency, and secured connectivity for video, display, and general-purpose applications.
For more information, please visit http://www.kinet-ic.com/.
*Kinetic Technologies’ logo is a trademark of Kinetic Technologies. All other brand and product names appearing in this document are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005531/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom